Inhibition of aromatase as treatment of @entity0 in postmenopausal XXXX .

@entity172 @entity1 @entity73057 @entity0 @entity28 @entity440 @entity5 @entity1910 @entity2055 @entity6239 @entity53 @entity19836 @entity701 @entity1815 @entity2671 @entity165 @entity33406
Recent treatment strategies have been directed toward blockade of @entity172 action or inhibition of @entity172 biosynthesis as a means of inducing regression of hormone-dependent @entity0 . The major source of @entity172 in postmenopausal @entity1 is the peripheral conversion of @entity2671 to @entity1815 through the enzyme aromatase. It is known that aromatase activity increases proportionately with degree of @entity28 in @entity1 . To test the importance of this modulatory factor, we correlated body weight with @entity172 excretion in our population of @entity1 with @entity0 and found significant relationships. In situ production of @entity53 from plasma precursors within @entity0 tissue may provide another source of @entity172 . Major enzymes mediating @entity172 biosynthesis were found to be present in @entity5 biopsy specimens. Aromatase activity was found to be present in 48/61 @entity1 @entity5 , sulfatase in 35/35, and @entity73057 in 41/41. One inhibitor of aromatase, @entity6239 , has been extensively studied in @entity1 with @entity0 . The additional effects of this drug on @entity165 side-chain cleavage and on 11-hydroxylase activity require coadministration of replacement glucocorticoid in treatment regimens. In pilot trials, 37% of @entity1 experienced objective @entity5 regression with a combination of 1000 mg @entity6239 and 40 mg @entity701 daily. In randomized clinical trials with this regimen, aromatase inhibition with @entity6239 produced @entity5 regression with similar frequency as did surgical hypophysectomy, surgical adrenalectomy, or @entity440 administration. The side effects of @entity6239 , including lethargy, @entity1910 , and @entity2055 complicate its use even though these problems are generally transient. Regimens of low-dose @entity6239 are being developed to reduce these side effects. Low-dose @entity6239 appears to block aromatase effectively and to have limited side effects, and is undergoing extensive clinical trial. A more specific aromatase inhibitor, @entity19836 , is now also being tested clinically, whereas @entity33406 , another new selective inhibitor, is undergoing study in animals.
